Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Does Diffusely Infiltrating Lobular Carcinoma of the Breast Arise from Epithelial-Mesenchymal Hybrid Cells?
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
- Publication Information:
Original Publication: Basel, Switzerland : MDPI, [2000-
- Subject Terms:
- Abstract:
Classic diffusely infiltrating lobular carcinoma has imaging features divergent from the breast cancers originating from the terminal ductal lobular units and from the major lactiferous ducts. Although the term "invasive lobular carcinoma" implies a site of origin within the breast lobular epithelium, we were unable to find evidence supporting this assumption. Exceptional excess of fibrous connective tissue and the unique cell architecture combined with the aberrant features at breast imaging suggest that this breast malignancy has not originated from cells lining the breast ducts and lobules. The only remaining relevant component of the fibroglandular tissue is the mesenchyme. The cells freshly isolated and cultured from diffusely infiltrating lobular carcinoma cases contained epithelial-mesenchymal hybrid cells with both epithelial and mesenchymal properties. The radiologic and histopathologic features of the tumours and expression of the mesenchymal stem cell positive markers CD73, CD90, and CD105 all suggest development in the direction of mesenchymal transition. These hybrid cells have tumour-initiating potential and have been shown to have poor prognosis and resistance to therapy targeted for malignancies of breast epithelial origin. Our work emphasizes the need for new approaches to the diagnosis and therapy of this highly fatal breast cancer subtype.
- References:
J Oncol. 2019 Apr 10;2019:2087983. (PMID: 31093281)
Eur J Radiol. 2022 Sep;154:110394. (PMID: 35751940)
Lancet. 1985 Apr 13;1(8433):829-32. (PMID: 2858707)
Lancet. 2000 Feb 5;355(9202):429-33. (PMID: 10841122)
Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2):. (PMID: 22300978)
Cancer. 2004 Oct 15;101(8):1745-59. (PMID: 15386334)
Eur J Radiol. 2022 Apr;149:110189. (PMID: 35151954)
Science. 1976 Jan 23;191(4224):295-7. (PMID: 1246614)
Surgery. 1946 Jan;19:74-99. (PMID: 21022022)
Int J Breast Cancer. 2014;2014:581706. (PMID: 25400950)
Radiology. 2021 Jun;299(3):541-547. (PMID: 33650900)
Virchows Arch. 2018 Jun;472(6):1007-1014. (PMID: 29101458)
Cancer. 2019 Feb 15;125(4):515-523. (PMID: 30411328)
Semin Cancer Biol. 2022 Dec;87:17-31. (PMID: 36354098)
Eur J Radiol. 2022 Jul;152:110323. (PMID: 35576721)
Breast Cancer (Auckl). 2014 Feb 25;8:15-38. (PMID: 24653647)
J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755. (PMID: 31216380)
Cancer. 2020 Jul 1;126(13):2971-2979. (PMID: 32390151)
Cell Stem Cell. 2019 Jan 3;24(1):65-78. (PMID: 30554963)
Eur J Radiol. 2022 Aug;153:110363. (PMID: 35605334)
- Grant Information:
Taiwan Association of Medical Screening; GINOP-2.3.2-15-2016-00020TUMORDNS National Research Development and Innovation Office of Hungary; OTKA K125509 National Research Development and Innovation Office of Hungary; OTKA PD138837 National Research Development and Innovation Office
- Contributed Indexing:
Keywords: biomarkers; breast neoplasms; early detection of cancer; histopathology technology; interdisciplinary communication; mammography; neoplastic stem cell; pathologists; patient care; precision oncology
- Publication Date:
Date Created: 20230714 Date Completed: 20230717 Latest Revision: 20230718
- Publication Date:
20240829
- Accession Number:
PMC10341583
- Accession Number:
10.3390/ijms241310752
- Accession Number:
37445938
No Comments.